Herriot Tabuteau, Axsome CEO
June 14, 2023 10:34 AM EDTUpdated 10:53 AM
R&D

Ax­some re­ports de­lay to PhI­II nar­colep­sy study, un­veils peak sales es­ti­mates on its drugs

Kyle LaHucik

Senior Reporter

Ax­some Ther­a­peu­tics ad­just­ed the time­line of a Phase III tri­al for an ex-Pfiz­er drug that it ex­pects to mar­ket for nar­colep­sy by 2025.

The New …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times